Overview
Q-Line Biotech IPO is an SME issue that opened for subscription on 21 May 2026 and is now listed. The issue aggregates ₹214.49 Cr.
IPO Details
Q-Line Biotech IPO is a Small and Medium Enterprise (SME) initial public offering scheduled to be listed on NSE SME. The issue has a price band of ₹326–₹343 per equity share with a lot size of 400 shares, translating to a minimum retail investment of ₹1,37,200.
The issue aggregates ₹214.49 Cr, with the subscription window open from 21 May 2026 to 25 May 2026. Allotment is expected on 26 May 2026 and the equity shares are scheduled to list on 29 May 2026.
- Type
- SME
- Status
- listed
- Price band
- ₹326–₹343
- Face value
- ₹10 (typical)
- Lot size
- 400 shares
- Min investment (Retail)
- ₹1,37,200
- Issue size
- ₹214.49 Cr
- Fresh issue
- —
- OFS
- —
- Exchange
- NSE SME
- ISIN
- TBA
- Sector
- Healthcare
Market Lot
Retail investors must apply for a minimum of one lot and can apply up to the retail cap of ₹2 lakh. NII / HNI investors apply above ₹2 lakh.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Minimum) | 1 | 400 | ₹1,37,200 |
| Retail (Maximum) | 1 | 400 | ₹1,37,200 |
| HNI / NII (Minimum) | 2 | 800 | ₹2,74,400 |
IPO Reservation
Per SEBI guidelines, Q-Line Biotech IPO reserves shares across investor categories as follows. Final allotment percentages may vary slightly based on the final issue document.
| Category | % Reserved | Notes |
|---|---|---|
| QIB | Up to 50% | Mutual funds, FIIs, banks |
| NII / HNI | Up to 15% | Bids ≥ ₹2 lakh |
| Retail | At least 35% | Bids up to ₹2 lakh |
Important Dates
- Issue Open21 May 2026 · Subscription opens
- Issue Close25 May 2026 · Subscription closes
- Allotment26 May 2026 · Basis of allotment finalised
- Refunds Initiated27 May 2026 · Funds released for non-allottees
- Listing Date29 May 2026 · Shares debut on the exchange
Grey Market Premium
Grey Market Premium for Q-Line Biotech is yet to be tracked. We update GMP from multiple grey market sources during the subscription window. Bookmark this page and check IPO GMP Today for live updates.
Subscription Status
Updated —
Allotment Status
Q-Line Biotech IPO allotment will be finalised by the registrar (TBA) on 26 May 2026. Check your allotment status using your PAN, application number, or DP ID via our allotment status checker or directly on the registrar's website.
If allotment fails, the blocked funds via ASBA / UPI mandate are released back within 24-48 hours. Applying through multiple demat accounts in family members' names improves chances on oversubscribed IPOs.
About Q-Line Biotech
Promoter & Holding Pattern
The promoter and promoter group hold the majority stake in Q-Line Biotech prior to the IPO. Post-listing, this percentage will reduce as new equity shares are issued to the public. Detailed pre-IPO and post-IPO promoter holding data will be updated once the Red Herring Prospectus is finalised with SEBI.
Objects of the Issue
The Q-Line Biotech IPO proceeds will be utilised across multiple strategic objectives. Typical objects include capital expenditure for expansion, repayment of debt, general corporate purposes, working capital, and OFS by selling shareholders. Detailed breakdown with amounts will be updated here from the Red Herring Prospectus.
Financial Performance
Q-Line Biotech's three-year financials — revenue, PAT, assets, net worth — will be displayed here based on audited numbers from the Red Herring Prospectus. Year-on-year growth, EBITDA margins, debt-to-equity progression, and RoNW together form the basis for valuation comparison.
Valuation Snapshot
Key valuation metrics for Q-Line Biotech — RoE, RoCE, EBITDA margin, PAT margin, debt-to-equity, EPS, P/E ratio, RoNW, NAV — will be updated based on FY25 numbers from the Red Herring Prospectus.
Peer Comparison
Listed peers in the Healthcare sector with key valuation metrics:
| Company | EPS (₹) | P/E Ratio | RoNW (%) | NAV (₹) | Income (₹ Cr) |
|---|---|---|---|---|---|
| Transasia Bio-Medicals (unlisted) | — | — | — | — | — |
| Tarsons Products | — | — | — | — | — |
Anchor Investors
Anchor investor bidding for Q-Line Biotech typically opens one working day before the issue opens to the public. Anchor investors — mutual funds, FIIs, sovereign wealth funds, and insurance companies — collectively subscribe to a portion of the QIB segment. Their participation signals institutional confidence. Anchor list and total amount will be updated once SEBI publishes the anchor filing.
Lead Managers (Merchant Bankers)
Book-Running Lead Managers (BRLMs) for Q-Line Biotech will be listed once confirmed in the Red Herring Prospectus. Lead managers oversee pricing, marketing, and underwriting — typically Kotak, ICICI Securities, Axis Capital, HDFC, SBI Caps, JP Morgan, or Citigroup.
IPO Registrar
The registrar for Q-Line Biotech IPO will be confirmed in the Red Herring Prospectus. The registrar handles allotment, refunds, and dematerialisation of shares.
Editorial Review
How to Apply for Q-Line Biotech IPO
- Open broker app — Zerodha, Upstox, Angel One, Groww, 5paisa, ICICI Direct, or any other SEBI-registered broker. Navigate to the IPO section.
- Select Q-Line Biotech IPO during the bidding window (21 May 2026 – 25 May 2026).
- Enter bid details — minimum 400 shares per lot. Retail investors are recommended to bid at cut-off price (₹343).
- Submit UPI ID linked to a SEBI-approved bank.
- Approve UPI mandate from your UPI app within the deadline. Bid amount is blocked, not debited.
- Await allotment on 26 May 2026.
- Listing day — shares list on NSE SME on 29 May 2026.